retatrutide weight loss trial results Lilly orforglipron oral GLP-1 phase 3 Retatrutide produces up to 30.3%

Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers

In July of this year, a bill entitled the Treat and Reduce Obesity Act of 2023 was introduced in the Senate with the explicit goal of lifting Medicares coverage exclusion for weight loss products, arguing that obesity increases the risk of multiple chronic conditions and thus costs the government billions of dollars

If your medication requires continuous refrigeration, consider a medical-grade cooling case specifically designed for injectable medications

The trend: Hims & Hers is offering prescription microdoses of compounded GLP-1 semaglutide, joining other telehealth companies promoting mini doses with lower costs and fewer side effects

R.HorwitzA.MouhammadZ